Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
François Ghiringhelli, R. Kim, T. Macarulla, I. Moreno et autres
fr, us, es, ca, dk (code pays fourni par la source)